➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Moodys
AstraZeneca
Colorcon

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Litigation Details for ERFINDERGEMEINSCHAFT UROPEP GbR v. Eli Lilly and Company (E.D. Tex. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

ERFINDERGEMEINSCHAFT UROPEP GbR v. Eli Lilly and Company (E.D. Tex. 2015)

Docket   Start Trial Date Filed 2015-07-01
Court District Court, E.D. Texas Date Terminated 2017-08-25
Cause 15:1126 Patent Infringement Assigned To William C. Bryson
Jury Demand Both Referred To
Parties BROOKSHIRE BROTHERS INC; DAVID FOLSOM; ELI LILLY AND COMPANY; ERFINDERGEMEINSCHAFT UROPEP GBR
Patents 6,455,557; 6,469,012; 9,393,238; RE38,115
Attorneys Adam K Mortara; Ahmed Jamal Davis; Alex L. Groden; Anthony H. Son; Benjamin J Whiting; Cherylyn Esoy Mizzo; David Folsom; Felicia J Boyd; J Scott McBride; Jeff M Barron; John M Hughes; John Wesley Samples; Jon Bentley Hyland; Melissa Richards Smith; Nosson Knobloch; Ruffin B Cordell; Sarah Marianne Cork; Todd G Vare; Victor D Vital
Firms Barnes & Thornburg LLP - Dallas; Barnes & Thornburg LLP Minneapolis; Fish & Richardson PC - Washington DC; Jackson Walker LLP; John Wesley Samples Attorney at Law Arlington
Link to Docket External link to docket
Small Molecule Drugs cited in ERFINDERGEMEINSCHAFT UROPEP GbR v. Eli Lilly and Company
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in ERFINDERGEMEINSCHAFT UROPEP GbR v. Eli Lilly and Company
The biologic drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for ERFINDERGEMEINSCHAFT UROPEP GbR v. Eli Lilly and Company (E.D. Tex. 2015)

Date Filed Document No. Description Snippet Link To Document
2016-08-08 129 Response in Opposition to Motion 9,393,238 issued July 19, 2016 and is assigned to Celgene. Ex. 53, App. at 1065. It claims a method… ’124 patent contributed to your conclusion that the claims of the ’124 patent lack written…potentially, thousands of patents and dozens of Lilly’s. 10 We will return to the patent at issue in Avanir…To Existing Patents, Including Lilly’s There are 27,465 United States patents with claims …numerous patents that could be dramatically impacted by Lilly’s argument. For example, U.S. Patent No. 9,393,238 External link to document
2016-08-08 130 Exhibit 67 - Canto (2009) 463756A1, # 4 Exhibit 53 - U.S. Patent 9,393,238, # 5 Exhibit 54 - Lilly Patents with Claim Term Inhibitor,…Inhibitor, # 6 Exhibit 55 - U. S. Patent 5,674,887, # 7 Exhibit 56 - U.S. Patent 6,451,807, # 8 Exhibit 57 - Sybertz…2009), # 19 Exhibit 68 - U.S. Patent 6,245,802, # 20 Exhibit 69 - U.S. Patent 6,492,371, # 21 Exhibit 70 … Sybertz (1995), # 9 Exhibit 58 - U.S. Patent 5,393,755, # 10 Exhibit 59 - EP 0579496 A1, # 11 Exhibit…Claim Construction Hearing, # 16 Exhibit 65 - U.S. Patent RE38,115 E, # 17 Exhibit 66 - Mayo Clinic List External link to document
2017-02-07 198 Motion in Limine 0001-5 2. Pfizer U.S. Patent No. 6,469,012 …Parte Reexamination Certificate for U.S. Patent No. 6,469,012 0053-87 4. Ex Parte…the ‘124 Patent”) nor prior art to the ‘124 Patent in an attempt to bolster the ‘124 Patent’s disclosure…compare the ‘124 Patent to Lilly’s U.S. Patent No. 6,451,807 (“the ‘807 Patent”) in both its present…Meaning, or Scope of the ‘124 Patent Drawn from Unrelated Patents. ........................ External link to document
2015-11-03 38 Response in Opposition to Motion at 1 (D.N.J. Oct. 11, 2007) (citing U.S. Patent No. 6,455,557). The district court in that case construed…Lilly and Brookshire infringe U.S. Patent No. 8,791,124 (“the ʼ124 Patent”) through the sale of Cialis® for…Direct Infringement of the ’124 Patent. Claim 1 of the ’124 Patent recites, in pertinent part, “… Brookshire for Direct Infringement of the ’124 Patent. .........................................7  …Brookshire for Indirect Infringement of the ’124 Patent. ....................................11  IV.  External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Moodys
Boehringer Ingelheim
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.